GKOS Glaukos Corp Forecast, Technical & Fundamental Analysis
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases... Show more
GKOS is expected to report earnings to rise 18.61% to -21 cents per share on July 29
Q2'26
Est.
$-0.21
Q1'26
Beat
by $0.10
Q4'25
Missed
by $0.69
Q3'25
Beat
by $0.10
Q2'25
Beat
by $0.02
The last earnings report on April 29 showed earnings per share of -18 cents, beating the estimate of -28 cents. With 379.55K shares outstanding, the current market capitalization sits at 9.02B.
A.I.dvisor indicates that over the last year, GKOS has been loosely correlated with ISRG. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if GKOS jumps, then ISRG could also see price increases.
The 10-day RSI Indicator for GKOS moved out of overbought territory on July 20, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 instances where the indicator moved out of the overbought zone. In of the 43 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 68 cases where GKOS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for GKOS turned negative on July 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 59 similar instances when the indicator turned negative. In of the 59 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GKOS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
GKOS broke above its upper Bollinger Band on June 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 24, 2026. You may want to consider a long position or call options on GKOS as a result. In of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The 10-day moving average for GKOS crossed bullishly above the 50-day moving average on June 18, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GKOS advanced for three days, in of 316 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 284 cases where GKOS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GKOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.441) is normal, around the industry mean (10.939). P/E Ratio (0.000) is within average values for comparable stocks, (64.127). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.958). GKOS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (16.026) is also within normal values, averaging (30.558).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
